Travere Therapeutics (TVTX) Change in Acquisitions & Divestments (2013 - 2026)

Travere Therapeutics (TVTX) has 14 years of Change in Acquisitions & Divestments data on file, last reported at $48.8 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 8.23% year-over-year to $48.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $319.2 million (up 19.06% YoY) and the FY2025 annual result came in at $323.6 million, down 0.84% from the prior year.
• Change in Acquisitions & Divestments slipped to $48.8 million in Q1 2026, from $82.4 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $152.6 million in Q2 2022 to a low of $48.8 million in Q1 2026.
• A 5-year average of $83.3 million and a median of $82.4 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments slumped 57.54% — and 2025, when it soared 96.29%.
• Tracing TVTX's Change in Acquisitions & Divestments over 5 years: stood at $52.4 million in 2022, then retreated by 4.55% to $50.0 million in 2023, then increased by 10.1% to $55.0 million in 2024, then surged by 49.72% to $82.4 million in 2025, then slumped by 40.81% to $48.8 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $48.8 million (Q1 2026), $82.4 million (Q4 2025), and $106.6 million (Q3 2025), per Business Quant data.